Filtered By:
Cancer: Chronic Leukemia

This page shows you your search results in order of date.

Order by Relevance | Date

Total 96 results found since Jan 2013.

Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies
Conclusions Inverse non-linear dose–response associations suggest substantial protection against a range of chronic disease outcomes from small increases in non-occupational physical activity in inactive adults. PROSPERO registration number CRD42018095481.
Source: British Journal of Sports Medicine - July 20, 2023 Category: Sports Medicine Authors: Garcia, L., Pearce, M., Abbas, A., Mok, A., Strain, T., Ali, S., Crippa, A., Dempsey, P. C., Golubic, R., Kelly, P., Laird, Y., McNamara, E., Moore, S., de Sa, T. H., Smith, A. D., Wijndaele, K., Woodcock, J., Brage, S. Tags: Open access, BJSM Reviews with MCQs, BJSM Systematic review Source Type: research

Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
CONCLUSIONS: The current CML treatment target is a cure that leads to normal age and gender-adjusted survival with a "normal" quality of life. Cardiovascular disorders are one of the major obstacles to reaching this target in CML patients. The treatment choices for CML patients must include a cardiovascular perspective.PMID:37401285 | DOI:10.26355/eurrev_202306_32786
Source: European Review for Medical and Pharmacological Sciences - July 4, 2023 Category: Drugs & Pharmacology Authors: U Y Malkan I C Haznedaroglu Source Type: research

Viruses, Vol. 15, Pages 1235: Ischaemic Stroke Occurring in a Patient Treated with Monoclonal Antibodies for COVID-19
In conclusion, among several side effects that have been described during the treatment of COVID-19 with sotrovimab, ischaemic stroke was not reported. Therefore, we here report a rare case of ischaemic stroke with early clinical manifestation after the administration of sotrovimab for the treatment of moderate COVID-19 in an immunocompromised patient for the first time.
Source: Viruses - May 25, 2023 Category: Virology Authors: Antonio Lobasso Ciro di Gennaro Maria Rita Poggiano Antonio Vasta Raffaele Angelo Nicola Ranucci Roberto Lobianco Anna Giacoma Tucci Enrico Cavagli à Pierpaolo Di Micco Tags: Case Report Source Type: research

Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies
CONCLUSIONS: Inverse non-linear dose-response associations suggest substantial protection against a range of chronic disease outcomes from small increases in non-occupational physical activity in inactive adults. PROSPERO registration number CRD42018095481.PMID:36854652 | DOI:10.1136/bjsports-2022-105669
Source: British Journal of Sports Medicine - February 28, 2023 Category: Sports Medicine Authors: Leandro Garcia Matthew Pearce Ali Abbas Alexander Mok Tessa Strain Sara Ali Alessio Crippa Paddy C Dempsey Rajna Golubic Paul Kelly Yvonne Laird Eoin McNamara Samuel Moore Thiago Herick de Sa Andrea D Smith Katrien Wijndaele James Woodcock Soren Brage Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news